metadata dict | overall dict | perCategoryPriceDrop dict | timeToFirstGenericHistogram dict | priceDropHistogram dict | stalledGenerics list | brandOnlyCohort list | evergreeningFlagDistribution dict | andaCompetitorPriceCurve dict | costPlusVsGoodRx dict | limitations list | attribution string |
|---|---|---|---|---|---|---|---|---|---|---|---|
{
"name": "RxGrab 2026 Brand-to-Generic Patent Cliff Audit",
"description": "Aggregated cost-drop, time-to-generic, and stalled-generic audit covering 50 high-volume US prescription drugs across 24 therapeutic categories.",
"sourceRecords": 50,
"categories": 24,
"timeRange": "1982-2026 (patent expiry years); ... | {
"n": 50,
"withApprovedGeneric": 45,
"brandOnly": 5,
"medianPriceDropPct": 85,
"meanPriceDropPct": 81,
"minPriceDropPct": 41,
"maxPriceDropPct": 97,
"medianMonthsToFirstGeneric": 11,
"meanMonthsToFirstGeneric": 19,
"stalledGenericCount": 7,
"stalledGenericPct": 15.6,
"with505b2LineExtension": 9... | {
"Cholesterol": {
"count": 4,
"avgPriceDropPct": 95,
"drugs": [
"atorvastatin",
"rosuvastatin",
"pravastatin",
"simvastatin"
]
},
"Mental Health": {
"count": 7,
"avgPriceDropPct": 92,
"drugs": [
"sertraline",
"escitalopram",
"fluoxetine",
... | {
"0-6_months": 21,
"7-12_months": 9,
"13-24_months": 6,
"25-47_months": 4,
"48_plus_months": 5
} | {
"under_50_pct": 2,
"50_to_69_pct": 5,
"70_to_84_pct": 10,
"85_to_94_pct": 18,
"95_pct_or_more": 10
} | [
{
"brand": "ProAir HFA",
"generic": "Albuterol HFA",
"category": "Asthma",
"firstGenericYear": 2020,
"twelveMonthRetainedPct": 78,
"stallDriver": "Authorized generic, single ANDA, device-formulation complexity"
},
{
"brand": "Suboxone",
"generic": "Buprenorphine/Naloxone",
"c... | [
{
"brand": "Ozempic",
"generic": "Semaglutide",
"category": "Diabetes / GLP-1",
"approxUS2024SalesUsdBn": 18.4,
"estimatedFirstGenericYear": "2031-2033",
"evergreeningFlag": false,
"iraNegotiated": false
},
{
"brand": "Wegovy",
"generic": "Semaglutide",
"category": "Weigh... | {
"no_evergreening_observed": 36,
"505b2_line_extension_within_36_months": 9,
"patent_thicket_documented": 5,
"citizen_petition_filed_against_anda": 4,
"rems_program_restricting_substitution": 3,
"authorized_generic_at_launch": 15
} | {
"1_holder_pct_of_brand": 81,
"2_holders_pct_of_brand": 49,
"3_holders_pct_of_brand": 30,
"4_holders_pct_of_brand": 19,
"5_holders_pct_of_brand": 12,
"6_plus_holders_pct_of_brand": 8,
"source": "FDA Generic Competition and Drug Prices (https://www.fda.gov/drugs/generic-drugs/generic-competition-and-drug-... | {
"drugsListedOnBoth": 32,
"costPlusCheaperCount": 30,
"averageGapPct": 67,
"drugsWithGapAbove80Pct": 9,
"exampleComparisons": [
{
"drug": "Atorvastatin 20mg (30-day)",
"costPlusUsd": 3.6,
"goodRxLowUsd": 9.83,
"gapPct": 63
},
{
"drug": "Sertraline 50mg (30-day)",
... | [
"Biologics and biosimilars excluded from headline drop median (Humira referenced as patent-thicket case context only).",
"Cash-price snapshots reflect Q1-Q2 2026 publicly posted pharmacy prices; insurance-negotiated and 340B prices may differ materially.",
"OTC-equivalent strengths excluded from prescription-st... | Cite as: RxGrab 2026 Brand-to-Generic Patent Cliff Audit, https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/ (CC-BY 4.0). |
RxGrab 2026 Brand-to-Generic Patent Cliff Audit
Aggregated cost-drop, time-to-generic, and stalled-generic audit covering 50 high-volume US prescription drugs across 24 therapeutic categories.
- License: CC-BY 4.0
- DOI: 10.5281/zenodo.20632747
- Source study: https://rxgrab.com/research/brand-to-generic-patent-cliff-2026/
- Author: Vincent Wesley Couey (ORCID 0009-0005-6869-308X) · published via RxGrab (rxgrab.com), part of the Lattice research network.
What's in it
Files: data.json. Main table stalledGenerics (7 rows): brand, generic, category, firstGenericYear, twelveMonthRetainedPct, stallDriver.
Method
Aggregates computed from RxGrab drug-database.json cross-referenced against FDA Orange Book, Drugs@FDA, CMS NADAC public files, GAO and ASPE drug pricing reports, IQVIA Use of Medicines public data, GoodRx public coupon-low prices, and Mark Cuban Cost Plus Drugs catalog. Price-drop percentage compares pre-generic brand cash price to post-generic median cash price 24 months after first ANDA approval. Stalled-generic flag applies where post-generic price retained 50 percent or more of pre-generic brand price for 12 or more months after first launch. Time-to-first-generic measured from FDA Orange Book composition-of-matter patent expiry (or settlement-permitted entry date) to first ANDA approval recorded in Drugs@FDA.
Citation
Couey, V. W. (2026). RxGrab 2026 Brand-to-Generic Patent Cliff Audit [Data set]. RxGrab. https://doi.org/10.5281/zenodo.20632747
CC-BY 4.0 — free to use with attribution. Informational and research use only. Not medical advice; verify against the primary source and a licensed professional before relying on any value. Dated snapshot; verify current values before relying on them.
- Downloads last month
- 20